<乌鸦传媒>Another Possible Option for HER2-Mutated Non-Small Cell Lung Cancer More than half of patients responded to antibody-drug conjugate targeting HER2 Sep 19, 2021
<乌鸦传媒>More Help on the Way for Lung Cancers With Exon 20 Mutations? Early trials of DZD9008 demonstrated responses in over a third of patients Sep 15, 2021
<乌鸦传媒>Cancer Vaccine May Boost Anti-EGFR Efficacy in Non-Small Cell Lung Cancer More than 90% disease control rate, hint of improved PFS in pilot trial Sep 14, 2021
<乌鸦传媒>Novel ADC Promising in Certain Non-Squamous Lung Cancers Response rate topped 50% in patients with EGFR wild-type tumors and high MET expression Sep 14, 2021
<乌鸦传媒>More Data in Support of Surgery for Malignant Pleural Mesothelioma Six-month improvement in overall survival with surgery plus chemotherapy versus chemo alone Sep 13, 2021
<乌鸦传媒>Meta-Analysis Confirms Benefits of Low-Dose CT Screening for Lung Cancer LDCT associated with a 16% relative reduction in mortality versus no screening Sep 13, 2021
<乌鸦传媒>Immuno-Oncology Combo Active in Recurrent EGFR/ALK Positive NSCLC Responses in 42% of EGFR group, limited activity in ALK-rearranged lung cancer Sep 12, 2021
<乌鸦传媒>Triplet Therapy Proves Safe in Resectable Malignant Pleural Mesothelioma Atezolizumab add-on offers promising outcomes in phase I trial Sep 12, 2021
<乌鸦传媒>Durable Response with Immunotherapy Combos in NSCLC with Brain Metastases Analysis of CheckMate 9LA data and phase II study from Spain offer hope in advanced disease Sep 12, 2021
<乌鸦传媒>Dual Immunotherapy Boosts Survival in Metastatic NSCLC Benefit with durvalumab-tremelimumab may vary by PD-L1 expression, histology Sep 10, 2021
<乌鸦传媒>Study Sheds Light on Physician-Assisted Suicide in Lung Cancer Patients Patients often did not consult with radiation or medical oncologists Sep 09, 2021
<乌鸦传媒>Second-Line Combo Fails to Improve Survival in SCLC No OS difference, but lurbinectedin-doxorubicin was less toxic than standard chemotherapy options Sep 09, 2021
<乌鸦传媒>High Response Rate in Non-Small Cell Lung Cancer With RET Inhibitor Responses in 66-80% of patients from China confirm activity of pralsetinib Sep 09, 2021
<乌鸦传媒>TROP2 Antibody-Drug Conjugate Shows Promise in Lung Cancer Disease control observed in over two-thirds of patients at selected dose Sep 08, 2021
<乌鸦传媒>Another Ivermectin Flop; 'Instant' Lung Cancer Decision Tool; Triple COPD Tx & Death Highlights from the European Respiratory Society virtual meeting Sep 08, 2021
<乌鸦传媒>No Survival Bump With PARP Inhibitor in Squamous NSCLC Possible benefit in tumors with positive lung cancer-specific gene panel Sep 07, 2021
<乌鸦传媒>Negative Trials Close the Book on Once-Promising SCLC Drug Poor tolerability doomed rovalpituzumab tesirine regimens in four clinical trials Sep 07, 2021
<乌鸦传媒>AI Blood Test Proves Useful in Lung Cancer Detection Such an approach would be useful considering the barriers to LDCT among high-risk people Aug 25, 2021
<乌鸦传媒>Avoiding Hippocampus in Brain RT May Help Preserve Cognitive Function Recall metrics favored hippocampal avoidance at all time points, with no increase in brain mets Aug 13, 2021
<乌鸦传媒>Kathy Griffin's Early-Stage Lung Cancer A closer look at diagnosis in "never-smokers" Aug 09, 2021
<乌鸦传媒>Drug Combo Promising in Rare Mesothelioma Small study showed "robust and durable" responses, with "meaningful prolongation of survival" Jul 19, 2021
<乌鸦传媒>Juul Bought Out Medical Journal for $51K E-cig maker sponsored nearly a dozen studies, took over journal as it awaits FDA ruling Jul 13, 2021
<乌鸦传媒>LDCT Screening Linked to Lower Risk of Brain Mets in Lung Cancer This observed reduction in risk may be due to a less aggressive tumor biology, said study author Jun 28, 2021
<乌鸦传媒>Start Thinking 'Cure'; One More Hug; Mortgages and Breast Cancer Survival News, features, and commentary about cancer-related issues Jun 16, 2021
<乌鸦传媒>Bispecific Antibody Active in NRG1-Positive Pancreatic Cancer Zenocutuzumab turns in promising results in early-phase trial involving multiple solid tumors Jun 10, 2021
<乌鸦传媒>Combination Shows Promise in Post-Osimertinib Lung Cancer Responses in 36% with amivantamab-lazertinib, 47% with EGFR/MET resistance Jun 06, 2021
<乌鸦传媒>Antibody-Drug Conjugate Active in Resistant Lung Cancer Responses in 39% of EGFR inhibitor-resistant patients with patritumab deruxtecan Jun 05, 2021
<乌鸦传媒>Chemoimmunotherapy Tied to Better Outcomes in Advanced NSCLC PD-L1 status and age play key roles in success of combined regimen versus immunotherapy alone Jun 05, 2021
<乌鸦传媒>Lymph Node Findings on PET: Cancer or COVID Vaccine? Post-jab radiotracer uptake "could prompt unnecessary biopsies and treatments" May 26, 2021
<乌鸦传媒>Anti-PD-L1 Plus SBRT Enhances Major Responses in Early NSCLC Neoadjuvant combo needs to be validated in a larger randomized trial May 20, 2021
<乌鸦传媒>PD-L1 Inhibitor Thwarts Recurrence in Early Lung Cancer Risk of death, recurrence 34% lower with atezolizumab after surgery and chemo May 19, 2021
<乌鸦传媒>Op-Ed: Is FDA's Cigarette Ban Just Smoke and Menthols? Actually implementing a ban on menthol cigarettes and cigars could take years May 03, 2021
<乌鸦传媒>SBRT Safe for Cancer Patients With Multiple Metastases Late adverse events in phase I trial indicate need for extended follow-up May 03, 2021
<乌鸦传媒>Lung Cancer Survival Continues to Rise With Immunotherapy Twice as many patients with advanced NSCLC alive at 5 years with pembrolizumab vs chemo Apr 29, 2021
<乌鸦传媒>Chemotherapy Nausea Linked to Stress, Neuropsych Symptoms High frequency of CIN leads to stress and more severe neuropsychological symptoms Apr 23, 2021
<乌鸦传媒>New Anti-PD1 Drugs Boost Survival in Treated Lung Cancer Questions about generalizability of results with China-developed therapies Apr 14, 2021
<乌鸦传媒>A Win for Nivolumab as Preoperative Therapy for Lung Cancer Pathologic CR rate 12 times higher with the addition of anti-PD-1 agent to chemo Apr 11, 2021
<乌鸦传媒>USPSTF Expands Lung Cancer Screening Criteria Lower age for starting, new definition of 'heavy smoker' double eligibility for screening Mar 09, 2021
<乌鸦传媒>Entrectinib Impresses in Certain Lung Cancers Durable responses in most patients with advanced NSCLC, active in brain mets Mar 05, 2021
<乌鸦传媒>New Targeted Therapies Show Promise in Cancer Selected abstracts from the ESMO Targeted Anticancer Therapies virtual meeting Mar 03, 2021
